180 likes | 262 Views
Biomarker-Guided HF Therapy: Is It Cost-Effective?. Age-Adjusted Hospitalization Rates for Heart Failure. Cost* of Heart Failure to Society. Diagnostic Uncertainty Is Associated With Poor Prognosis in Acute Dyspnea.
E N D
Diagnostic Uncertainty Is Associated With Poor Prognosis in Acute Dyspnea
Effect of Selective NT-proBNP Testing on CostsResults of the Randomized IMPROVE-CHF Trial
OPTIMIZE-HF BNP Measures and Death and Hospitalization at 1 Year
IMPROVE HF: Improvement in Quality Measures at 24 Months (Patient Level Analysis)
Challenges/Opportunities for Utilizing Biomarkers in the Management of Heart Failure
Thank you for joining us for this program. So, what would you do? What impact does this program on biomarkers have on your practice? As a reminder please join me on Medscape Discuss, a supplementary discussion by clicking the Join the Discussion button now. I am interested in hearing your thoughts and questions around this topic.